connexin

Connexin mimetic peptide 40,37GAP26, a biologically active peptide, matches the GAP26 domain of the extracellular loop of major vascular connexins Cx37 and Cx40, referred to as 37,40Gap26 based on Cx homology. It has been utilized to examine gap junctions' involvement in propagating endothelial hyperpolarizations induced by cyclopiazonic acid (CPA) in the rodent iliac artery wall. Abundant gap junction plaques comprising Cx37 and Cx40 are present in the endothelium, and the peptide exerts inhibitory actions on subintimal hyperpolarization.

Connexin mimetic peptide 40GAP27, corresponding to the GAP27 domain of the second extracellular loop of the dominant vascular connexin (Cx40), designated as 40Gap27, is a biologically active peptide utilized to study the pathways by which oxidant stress hinders gap junction communication. Administered 40Gap27 attenuates endothelium-dependent subintimal smooth muscle hyperpolarization.

Gap 26 is a mimetic peptide corresponding to the residues 63-75 of connexin 43, which is a gap junction blocker.

Gap19 TFA is a selective and potent blocker of connexin 43 (Cx43) hemichannels, originating from nine amino acids within the Cx43 cytoplasmic loop (CL). It operates by hindering intramolecular interactions between the C-terminus (CT) and the CL, effectively inhibiting hemichannel activity without affecting GJ channels or Cx40/pannexin-1 hemichannels. This peptide offers protective benefits for the myocardium.

Gap 27 is a peptide(Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin 43 that is a selective gap junction blocker.

Connexin43 mimetic peptide. Reduces swelling, astrogliosis, neuroinflammation and neuronal cell death following spinal cord injury ex vivo and in vivo. Exhibits analgesic effects in models of neuropathic pain. O'Carroll et al (2008) Connexin 43 mimetic peptides reduce swelling, astrogliosis and neuronal cell death after spinal cord injury. Cell.Commun.Adhes. 15 27 PMID:18649176 |Mao et al (2017) Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp.Brain.Res. 235 3033 PMID:28725925 |Kim et al (2017) Characterising the mode of action of extracellular Connexin43 channel mimetic peptides in an in vitro ischemia injury model. Biochem.Biophys.Acta. 1861 68 PMID:27816754 |Tonkin et al (2017) Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp.Neurol. 300 1 PMID:29055716

Gap19 TFA is a peptide derived from nine amino acids of Cx43 cytoplasmic ring (CL), an effective, selective connexin 43 (Cx43) half-channel blocker.

Peptide5 TFA, a connexin 43 mimetic peptide, mitigates swelling, astrogliosis, and neuronal cell death in animal models of spinal cord injury. Additionally, it suppresses the NLRP3 inflammasome, functioning as an anti-inflammatory agent [1] [2] [3].

Gap19 is a peptide that corresponds to a sequence on the cytoplasmic loop (CL) of Cx43.

Gap 26 TFA, a gap junction blocker, is a connexin mimetic peptide derived from the amino acid sequence 63-75 in the first extracellular loop of connexin 43, featuring the SHVR amino acid motif [1].